Alexion Pharmaceuticals Inc.

The sponsor demonstrates substantial commitment to advancing therapies for rare blood disorders and complement-mediated conditions. Research encompasses paroxysmal nocturnal hemoglobinuria, a life-threatening disorder characterized by hemolysis and thrombosis, with investigations into both intravascular and extravascular hemolytic activity. The portfolio extends to atypical hemolytic uremic syndrome, addressing complement dysregulation that leads to thrombotic microangiopathy.

• Complement component 5 inhibition strategies
• Treatment of clinically significant extravascular hemolysis
• Hematopoietic stem cell transplant-associated thrombotic microangiopathy
• Hemoglobin stabilization and transfusion independence

Therapeutic development includes both intravenous and subcutaneous formulations designed for pediatric and adult populations, with particular emphasis on pharmacokinetic and pharmacodynamic profiling across different age groups.